Free daily briefing on global business news.
The biotech said it will not advance SION-719 as an add-on therapy after the drug missed its key endpoint in a Phase 2a study
SOPA Images / Getty Images
Sionna Therapeutics reported Monday that its experimental cystic fibrosis drug SION-719 failed to meet the key activity endpoint in a mid-stage trial, sending the company's stock down 92%.
In the PreciSION CF Phase 2a trial, researchers assessed whether adding SION-719 to Trikafta would lower sweat chloride levels, a biomarker reflecting the functional activity of the cystic fibrosis protein. Results showed a mean placebo-adjusted sweat chloride reduction of just -1.0 mmol/L and a p-value of 0.7, the company said. Sionna said it will not advance SION-719 as an add-on to standard-of-care therapy.
